Q-Sera’s innovative blood clotting technology presented at leading international scientific conference

23th October, Melbourne, Australia– Q-Sera Pty Ltd (Q-Sera) will present scientific data demonstrating the advantages of its innovative blood clotting technology, this week in Durban, South Africa at the 23rd International Congress of Clinical Chemistry and Laboratory Medicine, IFCC Worldlab.

This Congress sees leading clinical and medical experts gather from around the world to learn about and share the latest breakthroughs in clinical science and laboratory medicine.

Serum is the gold standard for biochemical analysis of blood samples and is produced when blood clots. Standard serum tubes clot slowly but can also clot poorly leading to laboratory complications and are unable to clot the blood of some patients – such as anticoagulated cardiac patients or people taking common medicine such as warfarin or other oral anticoagulants. Q-Sera’s breakthrough technology seeks to provide a cost-effective solution to these problems.

At this week’s conference, Dr. Goce Dimeski representing Q-Sera will present a scientific poster which provides data demonstrating how Q-Sera’s new blood clotting technology, the recombinant prothrombin activator RAPClot®, is a true breakthrough.

Dr. Dimeski, an expert in the clinical testing of blood collection tubes and co-inventor of the Q-Sera technology said, “We have important data on a new serum production technology, showing effective blood clotting and serum production in highly anticoagulated bloods using three of the most common anticoagulants found in a hospital setting. Other data sets show that there is no change in analyte results when RAPClot® tubes are compared to standard rapid clotting tubes.”

By isolating protein in the venom of some of the world’s deadliest snakes in Australia and others from overseas, Q-Sera has patented a novel class of coagulation agents for use in blood collection tubes. These ‘prothrombin activators’ were initially sourced from snake venom but can now be produced from modified cell lines using standard pharmaceutical manufacturing processes.

Blood collection tubes are coated with RAPClot®, resulting in tubes that rapidly produce high quality serum, even if the blood sample contains anticoagulants. These benefits may translate into cost efficiencies and cost reductions for healthcare systems and enable improved outcomes for patients.

Q-Sera is actively commercialising this disruptive technology and is currently working with a number of multinational partners to bring this technology and its benefits to the market.